Cart 0
Ascat BANNER 2-1.png
 
VNP_4619.jpg

ReGISTRATION

Conference Fees

Consultant Fees

Early Bird-3 Days £350 / 1 day £145

Normal Rate- 3 days £430 / 1 day £170

Non-Consultants Fees

Early Bird- 3 days £299 / 1 day £125

Normal Rate- 3 days £355 / 1 day £150

Medical/Nursing Student Fees

Early Bird- 3 days £150 / 1 day £70

Normal Rate- 3 days £200 / 1 day £90

Sponsorship Queries

Email : StephanieLauren.Quirk@gstt.nhs.uk

DSC_2386.jpg
VNP_4514.jpg

Abstracts

Abstract Submissions Open 1st March and Closes 15th August 2019.

The abstract submission process is your opportunity to help shape the content, to share your work with your peers and raise your professional profile.

2019 categories include:

Basic sciences-pathology and pathophysiology

Newborn screening; community engagement

Clinical and community implementation research

Public Health and Health Education

Psychology, education and quality of life

Ageing and haemoglobinopathies

Other aspects of haemaoglobinopathies


VNP_5020.jpg

Day 1 - 21st October

09.05-10.20 - Recent Updates

Dr David Rees: Overview of Sickle Cell Disease

Dr Paul Telfer: Overview Thalassaemia

Dr Sebastian Lucas: Pathology in Haemoglobinopathies

10.40 - 12.50 – Long-Term Outcomes

Dr Mona El-Ghamrawy: Sickle Cell Disease in Egyptian Patients: A Single Centre Study at Cairo University

Dr Winfred Wang: Update on the SCCRIP (St. Jude, USA) Cohort

Dr Jennifer Knight-Madden: Jamaican Cohort

Dr Julie Makani: Sickle In Africa: Consortium for Health, Education and Research on Sickle Cell Disease in Africa

Dr Antonis Kattamis: Long term survival in thalassaemia

13.20 – 14.50 - Hydroxyurea Perspectives

Yemi Moses: Patient Experience

Dr Mariane de Montalembert: European Perspectives

Dr Patrick McGann: US Perspectives and Personalized Dosing

Dr Russell Ware: Research and practice - unanswered questions

15.10-16.40 - Educational Session

Dr Wally Smith: Pain in SCD phenotypes, a tip of the iceberg

Dr Kalpna Gupta: Opioids use: Is there adverse outcome in SCD?

Dr Ify Osunkwo: Transition from Paediatric to adults care

Feedback by EU Patient Panel

17.00- 17.50 - Sponsored Session- Bluebird Bio: Gene Therapy

DSC_2401.jpg
DSC_2570.jpg
VNP_5310.jpg
DSC_2741.jpg
VNP_4971.jpg

Day 2 - 22nd October


09.00-10.30 -Thalassaemia

Dr Ali Taher: How I manage medical complications of β-thalassemia in adults

Dr Maria Cappellini: Update on New therapies

Dr Antonio Piga: Fertility in Thalassemia Men and Women

Dr John Porter: Severe iron overload in Thalassaemia – The Choice of Combination therapy in chelation

10.50 - 12.10 – Curative Therapies for Haemoglobinopathies

Dr Krishnamurti Lakshmanan: The principle of Stem Cell Therapies in haemoglobinopathies

Dr Julie Kanter: Gene therapy in Sickle Cell Disease

Dr Alexis Thompson: Gene Therapy in Thalassaemia

Dr Josu de la Fuente: Bone marrow therapy in paediatric patients

13.20 - 15.15 - Chronic Organ Damage in Sickle Cell Disease

Dr Elizabeth Klings: Pulmonary hypertension, Cardiac Dysfunction and Venous Thromboembolism in SCD

Dr Claire Sharpe: Renal Transplantation in patients with Sickle Cell Disease

Mr Marcus Bankes: Avascular necrosis in SCD

Dr Atul Gupta: Asthma and SCD: Paediatric Perspectives

DSC_2496.jpg

Dr Francoise Bernaudin: Long-term treatment follow-up of children with SCD monitored with abnormal transcranial Doppler velocities.

13.20 - 15.15 -Psychology Session

Dr. Kofi Anie: Neuropsychological screening in Sickle Cell Disease

Dr. Marsha Treadwell: Patient reported outcomes for a cohort of adolescents and adults with sickle cell disease

Dr Jerlym Porter: Overview of hydroxyurea adherence

Dr Jane Hankins: mobile health applications to improve sickle cell care

Dr Hatel Bhatt: Psychosocial issues in young people living with SCD

Dr Raselle Miller: Innovative therapeutic intervention with people living with sickle cell disease – The ‘Tree of Life’

15.35 - 17.20- Global Priorities Perspectives in Haemoglobinopathies

Ifeyinwa Osunkwo: Sickle Cell Disease Patient Management Strategies and Satisfaction Levels

Dr Isaac Odame: Overcoming barriers to implementing newborn screening programmes for SCD in Africa

Dr Biree Andemariam: Patient advocacy in service provision

Dr. Beatrice Gulbis: Rare Anemias Consortium: Haemoglobinopathies

17:30-18:00- Sponsored Session

Day 3 - 23rd October

09.00 – 10.40 - Research Update in Haemoglobinopathies

Dr Erfan Nur: Adding azathioprine and hydroxyurea preconditioning to alemtuzumab/TBI may improve donor chimerism in matched sibling donor allogeneic stem cell transplantation in adult sickle cell patients

Dr Ambroise Wonkam: Genomics of SCD and Novel Therapeutic Interventions

Dr Marina Kleanthous: NGS-based genetic diagnostic panel for inherited rare anaemias and genetic modifiers retrieved from the ITHANET portal

Dr Aurelio Maggio: Development of a severity Score System for Thalassemia Syndromes

11.00 - 13.00 Plenary

Dr Anders Berggren: Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Daniel Dos Santos: Haemoglobinopathy HPLC cases

Dr Emma Drasar: Thalassaemia Case Scenarios

Dr Rachel Kesse-Adu: Sickle Case Scenarios

Dr Stella Chou: RH genotype matching for transfusion in SCD

13.00-14.00: Parallel session: GSTT Grand Round: A multi-dimensional approach to sickle cell disease

14.00 – 15.30: Comprehensive care for haemoglobinopathies

Dr Jo Howard: How I treat the older adult with SCD

Dr Janet Kwiatkowski: Oral Combination Chelation Therapy

Mr Eugene Oteng-Ntim: Pregnancy in Sickle Cell Disease

Dr Vishal Jayakar: Red Cell Morphology

15.30-16.30- Plenary oral abstract presentations

Dr Jamie Kawadler: Longitudinal patterns of daily pain in children with sickle cell anaemia: association with executive function

Dr Diana Otabil: Adherence To Hydroxyurea Therapy And Quality Of Life In Children With Sickle Cell Disease In Korle Bu Teaching Hospital, Accra, Ghana

Dr Muattaz Kazzam: Adherence to Individualised Sickle Analgesia Plans by the Ambulance and A&E Services - A Single Centre Clinical Audit

Dr Dean Smyth: The Changing Demographics of Sickle Cell Disease in Scotland: Implications for Health Care Delivery.

VNP_5306.jpg
DSC_2367.jpg
DSC_3445.jpg

 

VNP_5429.jpg